Coronary hemodynamic and myocardial metabolic responses before and after perhexiline administration were studied in 21 patients with coronary heart disease during pacing-induced angina pectoris. Perhexiline increased the threshold to tachycardia-induced angina pectoris in 16 of the 21 patients (HR 123 ± 3 to 134 3 beats/min, P < 0.01). Anaerobic myocardial lactate extraction was reduced by -6.1 ± 6.3 to 10.7 4% after perhexiline, although lactate extraction declined in four patients This investigation was undertaken to examine the effects of perhexiline in a group of coronary heart disease patients with angina pectoris to further elucidate its clinical, coronary hemodynamic, and metabolic actions. Atrial pacing was employed to evoke angina thereby circumventing perhexiline's effect on heart rate during stress noted in previous studies. 1, 3, 4This method of evaluating patients with decreased coronary reserve produces chest discomfort indistinguishable from angina pectoris, ischemic electrocardiographic ST segment depression, and left ventricular hemodynamic and lactate abnormalities.9 The ability of this technique to evaluate a number of therapeutic interventions has recently been demonstrated.'0' " Changes in chest pain and coronary flow, as reflected by coronary sinus blood flow, systemic hemodynamics, and myocardial lactate and oxygen metabolism occurring during the stress of controlled tachycardia, were compared before and after perhexiline administration.
STUDIES HAVE SUGGESTED that perhexiline, 2-(2, 2-dicyclohexylethyl) piperidine, prevents or reduces the severity of exercise-induced angina pectoris." 2, , 4 Potent coronary and systemic hemodynamic effects have been observed in animals following perhexiline that indicate improved myocardial perfusion and peripheral vasodilatation. 5' 6 Studies in angina patients demonstrate lowered indices of myocardial oxygen demand during effort as a result of reduced tachycardia" 4 without significant depression of parameters of myocardial function.3 Additionally, recent studies have suggested that this agent has antiarrhythmic properties7 and a very prolonged half-life of elimination, T 1/2 > 3 days.8 Such actions would be potentially beneficial in patients with ischemic heart disease. Perhexiline is chemically unrelated to currently used antianginal agents.
This investigation was undertaken to examine the effects of perhexiline in a group of coronary heart disease patients with angina pectoris to further elucidate its clinical, coronary hemodynamic, and metabolic actions. Atrial pacing was employed to evoke angina thereby circumventing perhexiline's effect on heart rate during stress noted in previous studies. 1, 3, 4This method of evaluating patients with decreased coronary reserve produces chest discomfort indistinguishable from angina pectoris, ischemic electrocardiographic ST segment depression, and left ventricular hemodynamic and lactate abnormalities. 9 The ability of this technique to evaluate a number of therapeutic interventions has recently been demonstrated.'0' " Changes in chest pain and coronary flow, as reflected by coronary sinus blood flow, systemic hemodynamics, and myocardial lactate and oxygen metabolism occurring during the stress of controlled tachycardia, were compared before and after perhexiline administration.
Methods Twenty-one patients aged 44-61 years (mean 51) with chronic stable angina pectoris and angiographically significant (>75% obstruction) coronary artery disease (table 1) without evidence for heart failure or other forms of heart disease were studied. Other antianginal agents were stopped at least one week prior to study but nitroglycerin was permitted until the day of study. After informed consent was obtained to participate in this study, all subjects were studied in a fasting state without premedication and before angiocardiography. Systemic Abbreviations: C = Control-Rest; P = Control-Pacing; Cp = Rest after perhexiline; Pp = Pacing after perhexiline at P heart rate; Pp' = Pacing after perhexiline at angina. TTI, LVWI, CSBF, or CR when compared to values reached before perhexiline. In the 16 patients who tolerated greater tachycardia stress, the increase in TTI before angina during perhexiline treatment (Pp') was highly significant (P < 0.001).
Myocardial Metabolic Data
At rest (C) average myocardial lactate extraction was normal, +16.6% ( fig. 2 ), but five patients showed less than 10% extraction suggesting myocardial anaerobiosis. Arterial -coronary sinus oxygen difference ( fig. 3 ) varied widely and averaged 65%. Following perhexiline (Cp) average lactate extraction (XL) was 25.3%, a nonsignificant increase with four patients demonstrating less than 10% extraction. Average oxygen extraction and LVVO2 were unchanged.
With tachycardia LVVO2 increased 52% (P < 0.05). Lactate extraction declined significantly in 17 patients. Measurements in 13 patients showed extractions of less than 10% and eight of these revealed lactate production. Although most patients did not demonstrate negative lactate extractions during pacing-induced angina prior to perhexiline treatment, the mean of -6.1 ± 6.3% during control pacing was increased to + 10.7 + 4 after perhexiline treatment suggesting improved lactate metabolism. In the 16 patients without angina at this level of pacing stress (PP), XL increased in 12. In each of the eight lactate producers during P, XL improved during Pp. In four patients, XL declined paradoxically after perhexiline during P. Oxygen extraction widened during Pp to 69%, P < 0.02, compared to 64% with P, and accounted for an increased LVVO2, 20.9 ml/min compared to 18.9 ml/min, P < 0.05 ( fig. 1 ). In the 16 patients not experiencing angina at this heart rate (Pp), the increase in XL correlated (P < 0.05) with the increase in oxygen extraction.
Discussion
This study was undertaken to clarify the possible coronary action of perhexiline in angina patients with coronary artery disease. Following continuous oral administration, we found that most patients remained free of angina or experienced less severe pain during the same tachycardia stress while achieving similar cardiac tension and work indices. Significant increases in the tachycardia-induced angina threshold were associated with increased myocardial oxygen utilization. Presumably, pacing-induced increases in myocardial oxygen requirements expose limitations in coronary vascular reserve to augment myocardial oxygen delivery. Since myocardial oxygen utilization is limited by the amount of oxygen delivered, increased oxygen utilization without manifestations of ischemia implies that perhexiline improves oxygen delivery.
The absence of significant increases in total left ventricular coronary flow is suggested by lack of increases in coronary sinus blood flow or narrowing of the arterial -coronary sinus oxygen difference. The fact that the arterial -coronary sinus oxygen difference actually increased after perhexiline could be interpreted to reflect increased myocardial oxygen requirements, a potentially deleterious effect in patients with limited coronary vascular reserve. Although it is possible that such an anomalous effect could occur in the absence of changes in the tension-time index by increasing ventricular contractility or volume, it would also have effected increased ischemia with exacerbation of accompanying clinical and metabolic manifestations. Since such responses are at variance with what we observed, the above possibility seems unlikely.
Using myocardial lactate fluxes as an index of anaerobiosis added support to the impression that net oxygen requirements were not increased on perhexiline. Although substantial individual variations occurred and levels in most patients did not demonstrate negative lactate extractions during pacing-induced angina prior to perhexiline treatment, the mean value of -6.3% during control pacing was increased to +10.7% after perhexiline administration, indicating improved lactate extraction in certain patients ( fig. 2) usual changes in coronary sinus flow did not occur, a possible deleterious effect could not be definitely excluded in these four cases.
The increased oxygen extraction occurring after perhexiline could be explained by a variety of mechanisms. Since patients with coronary heart disease have scattered areas of myocardial hypoxia, there is wide individual variation in oxygen extraction17 as coronary sinus blood predominantly reflects venous effluent from normally perfused myocardial segments.'8 Coronary sinus oxygen saturation is often unusually high in these patients, also implying that the vascular bed may be chronically dilated in regions of normally perfused myocardium. ' 20 Because of the regional nature of coronary artery disease over-all coronary flow and coronary sinus oxygen concentration may not necessarily reflect abnormalities occurring in several discrete areas. Accordingly, speculation with regard to mechanism of action of this compound is probably not warranted. It would seem that considerable clarification of these actions may be obtained by measuring the effect of this agent in the absence of such variables introduced by the diseased coronary circulation.
It has been postulated on the basis of several studies in anesthetized animals that perhexiline has a direct action on the coronary circulation.5' f, 21 Rowe, Spring, and Afonso2' observed constriction of dog coronary arteries following direct intracoronary infusion of perhexiline solution. This occurred despite the known coronary vasodilating effects of both prior and subsequent injections of angiographic contrast material. Although constriction was not observed after right atrial administration, small doses of perhexiline (0.3 mg/kg/min) produced a decline in coronary flow as coronary resistance increased. As Our data suggest that perhexiline has favorable coronary metabolic actions in patients with a diseased coronary circulation. Although the exact mechanism of action has not been determined, this study lends support to earlier clinical observations implying actions which lessen myocardial ischemia. These effects extend the threshold to tachycardia-induced angina pectoris, lessen myocardial anaerobic lactate metabolism, and are associated with enhanced myocardial oxygen extraction. Since this agent also reduces exercise heart rate, lessening the myocardial oxygen requirement while improving the stroke workleft ventricular filling pressure relationship,3 it appears to be worthy of additional evaluation in patients with angina pectoris. The drug seems to be relatively well tolerated24 and may also prove to be useful in angina patients who are unresponsive to other agents25 or in whom use of beta-blocking agents is limited by compromised myocardial function or bronchospasm.26
